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Effect of plasma levels of parathyroid hormone on NADPH pathways in
kidney and liver. NADPH available for mixed function oxidations
(pathway 1) or biosynthetic processes (pathway 2) has been evaluated
in different cells from rat liver and kidney. In addition, changes of the
proportion of NADPH utilized in each pathway were demonstrated in
the same cells from rats showing different circulating levels of
parathyroid hormone (PTH). Quantitative levels of NADPH directed
into each of these pathways have been measured and histologically
located in sections from rat liver and kidney using quantitative
cytochemistry and scanning and integrating microdensitometry.
Centrilobular hepatocytes utilize the major amount of NADPH, either
via pathway I or 2. Kidney cells utilize most NADPH via pathway 2,
particularly in the distal part of the nephron. The cells of the pars recta
have shown the highest capacity to utilize NADPH via pathway 1,
which is about half that of centrilobular hepatocytes. In centrilobular
cells, the presence of high plasma levels of PTH results in a significant
increment of NADPH utilization either via pathway 1 or 2. In kidneys
from rats showing high plasma levels of PTH, a selective increase in
NADPH utilized via pathway 2 was observed in the distal convoluted
tubule whereas a selective increase in NADPH utilized via pathway I
was demonstrated in cells of the pars recta. These observations provide
further information in the understanding of the physiology of kidney
and liver cells.
Effet des concentrations plasmatiques d'hormone parathyroidienne sur
les voies d'utilisation du NADPH dans le rein et le foie. La quantité de
NADPH utilisée soit dans Ia voie des activités monooxygénase (vole 1),
soit dans des biosynthéses réductives (voie 2) a été mesurée au niveau
de différents types cellulaires du foie et du rein de rat. En paralléle,
nous avons étudié ces deux voies d'utilisation du NADPH sur les
mémes cellules provenant de rats dont les concentrations circulantes
d'hormone parathyroidienne (PTH) différaient. Les voies d'utilisation
du NADPH ont été étudiées et histologiquement définies moyennant
des techniques de cytochimie quantitative et de microdensitométrie.
Nos résultats ont montré que les hépatocytes centrilobulaires utilisent
le maximum de NADPH aussi bien dans Ia voie 1 que 2. En revanche,
les cellules du rein examinées utilisent le NADPH de préférence par Ia
voie 2, en particulier celles de Ia partie distale du nephron. Les cellules
de la pars recta possédent Ia capacité maximale pour utiliser Ic NADPH
a travers la vole 1, bien que cette capacite n'atteigne pas Ia moitié de
celle des hepatocytes centrilobulaires. Dans les hépatocytes
centrilobulaires, la presence de concentrations plasmatiques élevées de
PTH conduit a une augmentation significative de l'utilisation du
NADPH aussi bien dans la voie 1 que 2. Dans les cellules du tubule
contournC distal de rats hyperparathyroIdiens, une augmentation
selective du NADPH utilisé dans la voie 2 a etC dCmontrCe, tandis
qu'une augmentation selective de l'utilisation du NADPH par la vole I
a ete démontrCe dans les cellules de Ia pars recta de ces rats. Ces
observations fournissent des informations supplCmentaires en vue
d'une meilleure connaissance de la physiologic des diffCrents types
cellulaires du rein et du foie.
401
The pentose phosphate pathway operates at an elevated level
in both liver and kidney according to the high activity of
glucose-6-phosphate dehydrogenase (0-6-PD) in these organs.
NADPH supply to be used as a reducing agent is one of the
main functions of this activity. NADPH can be used either
indirectly, via the electron carrier chain associated with mixed
function oxidations and cytochrome P450 (pathway 1) or di-
rectly as a source of reducing equivalents in many reductive
biosynthesis (pathway 2). The amount of NADPH channelled
into each of these pathways is variable and related to the
physiology of the cell. In addition, there are mechanisms that
adjust the rate of G-6-PD activity to requirements.
In the present work, 0-6-PD activity and the proportion of
reducing equivalents involved in each pathway have been
investigated in liver cells and in cells belonging to the different
segments of the nephron, as an approach to further elucidate
the function of these cells.
In the kidney, parathyroid hormone (PTH) stimulates 0-6-PD
activity in a dose-dependent way [11 and controls I a-hydroxyl-
ase activity [21, the mixed function oxidase required for the
production of the hormonal form of vitamin D3 [31. As both
activities are related to NADPH pathways, the influence of
circulating levels of PTH on the utilization of the reduced
coenzyme was evaluated along the rat nephron. The proportion
of NADPH utilized in each pathway in the kidney was com-
pared with the proportion determined by similar experiments in
liver cells.
Cytochemical assays of NADPH were carried out involving
the precipitation of a colored end-product followed by its
measurement using scanning and integrating microden-
sitometry. The mass of a chromophore precipitated in a cell by
the action of an enzymatic activity can be measured precisely
and rapidly by these techniques as it has been previously
demonstrated [4, 51.
Within such a heterogeneous organ as the kidney, these
methods provide a powerful tool for the elucidation of bio-
chemical mechanisms occurring in individual cell types.
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Methods
Three groups of female Wistar rats, exhibiting low, normal,
and high circulating levels of PTH, respectively, were prepared
as follows: The group with low levels of PTH (TPTX) was
obtained by surgical removal of the thyroid parathyroid com-
plex under ether anesthesia. On day 3 after surgery, these
animals were used in the experiments. Their circulating level of
PTH was 21.1 5.1 pg/ml and their plasma calcium level was
1.4 0.3 mii (±sEM). Sham-operated animals had normal
levels of PTITI (N). Their circulating level of PTH was 44.2
1.4 pg/mi and their plasma calcium level was 2.3 0.1 mM
(± SEM). The third group of rats with high levels of PTH(HPTH)
was obtained by feeding the rats a vitamin D deficient diet for 5
to 7 weeks after weaning. Their circulating PTH levels were
141.6 10.1 pg/ml, and their plasma calcium level was 1.3
0.1 m (± sEM). All groups were killed by asphyxiation in a
nitrogen atmosphere.
Pieces of kidney and liver tissue (5 x 3 x 3 mm) were chilled at
—70°C as described by Chayen [6]. Fresh, unfixed l0-m tissue
sections were obtained in a Bright's automated cryostat and
were incubated at 37°C for 10 to 15 mm in a medium containing:
glucose-6-phosphate, 5 mrvi (Sigma Chemical Co., St. Louis,
Missouri, USA); NADP, 3 mri (Boehringer); neotetrazolium
chloride, 5 m (Sigma Chemical Co.); polyvinyl alcohol, 30%
w/v (Wacker Chemie), in 50 mrt glycylglycine buffer (pH 8).
The incubations were performed in a nitrogen atmosphere.
NADPH generated by G-6-PD activity reduces neotetra-
zolium chloride to a colored insoluble formazan which precipi-
tates at the site where it was reduced. Because neotetrazolium
chloride must be reduced at a very high electrode potential
relative to NADPH, the reduction of this tetrazolium salt in the
absence of any artificial electron acceptor involves the transfer
of reducing equivalents along the electron transfer chain, to the
terminal oxidase, cytochrome P450. The amount of formazan
precipitated is therefore proportional to NADPH pathway 1.
The addition of the electron carrier phenazine methosulfate to
the incubation medium (0.67 m, Sigma Chemical Co.) allows
the direct transfer of the total amount of reducing equivalents
from NADPH to neotetrazolium chloride. By subtracting
NADPH pathway I measured in the absence of phenazine
methosulfate from total NADPH measured in the presence of
phenazine methosulfate, it is possible to calculate the amount of
NADPH entering pathway 2.
These experimental conditions have been described by Alt-
man [4] who established that the reactions were linear with
incubation time and with the thickness of the section (equiva-
lent to different concentrations of enzyme preparation). Ad-
ditionally, the formazan production has been shown to be linear
with increasing concentrations of neotetrazolium chloride,
NADP, and glucose-6-phosphate, until all the NADPH pro-
duced has been precipitated in formazan [4]. In preliminary
experiments, we confirmed these experimental conditions.
The amount of formazan precipitated was measured in single
cells by scanning and integrating microdensitometry, using a
microdensitometer (Vickers M 85) at the isosbestic wavelength
of 585 mm, with a x40 objective, a mask of 12.5 pm of diameter
and a scanning spot of 0.5 pm of diameter. Results were
expressed as the mean SEM of the integrated extinction X 100
(MIE xlOO).
Table 1. Distribution of G-6-PD activity and NADPH pathways in the
rat liver, (MIEx 100)110 min°
Hepatocyte G-6-PD
NADPH
pathway 1
NADPH
pathway 2
Pathway 2/
pathway 1
Periportal 23.9 2.4 12.5 1.1 11.4 1.7 0.9
Centrilobular 40.8 1.7 24.5 1.7 16.2 2.2 0.7
Each value is the mean SEM of results obtained in ten rats.
Centrilobular hepatocytes were measured around branches of
the hepatic vein, at the center of the lobule, and periportal
hepatocytes were distinguished near portal tracts at the lobule
margins.
Individual cell types within kidney segments were defined
histologically by their typical distribution in longitudinal sec-
tions and by their morphological characteristics. Measurements
in cells from the proximal convoluted tubule (PCT), from the
distal convoluted tubule (DCT), and from the cortical thick
ascending limb of Henle's loop (CTAL) were made in the
cortex. Activities present in cells of the pars recta (PR) were
measured in the outer stripe of the outer medulla whereas
activities present in cells from the medullary thick ascending
limb of Henle's loop (MTAL) were measured in the inner stripe
of the outer medulla. Measurements in cells from the collecting
tubule (CT) were made in the inner medulla.
Circulating levels of PTH were measured by radio-
immunoassay using a modified version of the method of
Arnaud, Tsao, and Littledike [7], with a lamb antiserum (AS M
747B, a gift from Dr. J. Guéris, Lariboisiére Hospital, Paris,
France) directed at the 53-84 hPTH fragment, synthetic 53-84
fragment as standard, and '251-tyr-53-84 hPTH as a tracer.
Cross-reactivity with the rat PTH was done with a
hyperparathyroid rat plasma and the curve thus obtained was
parallel to the standard curve. Normal rat plasma values were
20 to 90 pg/ml.
Plasma calcium levels were measured by atomic absorption
using a spectrophotometer (model 305, Perkin Elmer, Norwalk,
Connecticut, USA).
Statistical calculations were performed using the unpaired
Student's t test.
Results
In the liver, G-6-PD activity was maximal in centrilobular
hepatocytes 40.8 1.7 MIE x 100 (± SEM) (Table 1). In these
cells, NADPH utilized in pathway 1 was not significantly
different from the amount of NADPH entering pathway 2.
In centrilobular hepatocytes, the amount of NADPH utilized
in pathways 1 and 2 increased significantly in HPTH rats
compared with TPTX or N rats (P < 0.01). No significant
differences were observed in periportal hepatocytes between
the three groups of rats (Fig. 1).
In the kidney, the amount of NADPH entering each of these
two pathways differed widely along the nephron and appeared
to be independent from the total G-6-PD activity. NADPH
entering pathway 2 predominated in all the segments, especially
in cells from the DCT [23.5 2.2 MIE x 100 (± sEM)] and in
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Fig. 1. NADPH utilized in pathways I and 2 measured in centrilobular
(CL) and periportal (PP) hepatocytes from rats with low (0), normal(), and high (•) plasma levels of PTH. Results are the mean SEM
from experiments performed in eight rats.
Table 2. Distribution of G-6-PD activity and NADPH pathways along
the rat nephron, (MIEx 100)/15 mina
Segment G-6-PD
NADPH
pathway I
NADPH
pathway 2
Pathway 2/
pathway I
Proximal convo-
luted tubule 23.3 2.0 9.9 2.8 13.4 2.1 1.3
Pars recta 25.3 1.4 11.9 1.7 13.4 1.4 1.1
Medullary thick
ascending limb 24.4 2.7 4.4 0.8 19.9 2.4 4.5
Cortical thick
ascending limb 28.5 2.0 5.0 0.8 23.5 2.2 4.7
Distal convoluted
tubule 29.4 1.1 5.9 1.3 23.5 2.1 3.9
Medullary col-
lecting tubule 11.4 1.9 3.5 0.8 8.7 1.6 2.4
a Each value is the mean SEM of results obtained in ten rats.
cells from the CTAL [23.5 2.1 MIEx 100 (± sEM)] (Table 2).
The cells belonging to the proximal tubule and particularly
those from the pars recta utilized the maximal amount of
NADPH via pathway 1 [11.9 1.7 MIEx 100 (±sEM)} (Table
2).
In cells of the PR, increased plasma levels of PTH were
associated with an increased amount of NADPH channelled
into pathway I (P < 0.01) without affecting NADPH entering
pathway 2. In contrast, our results obtained in the DCT
demonstrated a significant and selective increase in the amount
of NADPH utilized in pathway 2 in rats with high plasma levels
of PTH (P < 0.05, Fig. 2).
NADPH pathway 2
Fig. 2. NADPH utilized in pathways 1 and 2 measured in proximal
convoluted tubules (PCT), pars recta (PR), medullar thick ascending
limb (MTAL), cortical thick ascending limb (CTAL), distal convoluted
tubules (DCT), and inner medullar collecting tubules (MCT)from rats
with low (0), normal (), andhigh (•)plasma levels of PTH. Results
are the mean SEM from experiments performed in eight rats.
Discussion
The large amount of NADPH channelled into pathway 1 in
centrilobular hepatocytes agrees with other observations [8]
and reflects the great capacity of these cells to metabolize drugs
as it is now well established [91.
The acute changes observed in G-6-PD activity and NADPH
utilization in centriobular hepatocytes from animals showing
different circulating levels of PTH outline the importance of
these cells as major target cells for PTH, at least as far as its
influence on NADPH pathways is concerned.
The larger amount of NADPH utilized via pathway 2 in
centrilobular hepatocytes from rats with higher plasma levels of
PTH is consistent with the well known effect of the hormone in
liver regeneration [10]. A clear relationship has been estab-
lished between the pentose phosphate pathway, NADPH uti-
lized in pathway 2 and DNA synthesis [1111.
Additionally, in centrilobular hepatocytes, increased plasma
levels of PTH result in an enhanced amount of NADPH
directed into pathway 1, raising the possibility of a control of
liver-mixed function oxidases by the hormone. Such effect
could be related to the control of 25-hydroylase, the mixed
function oxidase regulating vitamin D3 metabolism in the liver
[12].
In the kidney G-6-PD activity was maximal in the DCT and
the CTAL. Our results on the distribution of G-6-PD activity
along the nephron agree well with some previously published
reports in the rat nephron [13, 14] and the rabbit nephron [15].
However, we have been unable to confirm the high activity
demonstrated in glomeruli, thin limbs of Henle's loop, and
medullary collecting tubule by bioluminescence procedures
[16].
G-6-PD activity present in the distal tubule, was about one
haff compared with the activity measured in centrilobular
hepatocytes, and the amount of NADPH produced was mainly
404 Bachelet et a!
directed into pathway 2. Therefore, the major function of
cytoplasmic NADPH in these cells is probably related to
general growth and lipogenesis.
In the proximal tubule, NADPH entering pathway 2 could be
involved mainly in reducing glutathione because in these cells
the concentration of glutathione has been shown to be higher
117]. Whether NADPH directed into pathway 2 is utilized either
in lipogenesis or in reducing glutathione in the different seg-
ments of the nephron would merit additional investigation.
It is noteworthy that cells from the pars recta utilize the
maximal amount of NADPH via pathway 1, agreeing with other
histochemical observations [18]. Thus, this segment possesses
the maximal ability to metabolize drugs and steroids in the
nephron via mixed function oxidase activities. In agreement
with this finding is the fact that studies in microdissected
tubules demonstrate that the PCT and particularly the PR
possess a high la-hydroxylase activity [19, 201; the mixed
function oxidase catalizes the production of the hormonal form
of vitamin D3 in the kidney [3] under the control of PTH [2]. In
addition, cytochrome P450 activity has been shown to be
maximal in these cells [21].
The greater amount of NADPH channelled into pathway 1 in
the PR, observed in HPTH rats certainly can be associated with
the physiological role of the hormone in controlling 1 a-hydrox-
ylase activity.
A specific link between kidney growth and the pentose
phosphate pathway has been described already, after unilateral
nephrectomy [22]. Our results in the DCT, observed in animals
showing high plasma levels of PTH suggest a significant role of
PTH in this process. However, whether this effect of PTH in
the DCT could be related to the control of the active reabsorp-
tion of calcium by the hormone in these cells [231 merits further
investigation.
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